<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00001188</url>
  </required_header>
  <id_info>
    <org_study_id>830212</org_study_id>
    <secondary_id>83-C-0212</secondary_id>
    <nct_id>NCT00001188</nct_id>
  </id_info>
  <brief_title>The Role of Multi-Modality Therapy for the Treatment of High-Grade Soft Tissue Sarcomas of the Extremities</brief_title>
  <official_title>The Role of Multi-Modality Therapy for the Treatment of High-Grade Soft Tissue Sarcomas of the Extremities</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      Patients with Grade II and III soft tissue sarcomas of the extremity will be randomized to&#xD;
      either receive or not receive radiation therapy following surgery for the removal of the&#xD;
      local tumor. All patients in this protocol will receive adjuvant chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with Grade II and III soft tissue sarcomas of the extremity will be randomized to&#xD;
      either receive or not receive radiation therapy following surgery for the removal of the&#xD;
      local tumor. All patients in this protocol will receive adjuvant chemotherapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 1983</start_date>
  <completion_date>September 2000</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>100</enrollment>
  <condition>Sarcoma</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>radiation therapy following surgery</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Patients must have biopsy-proven soft tissue sarcoma with one of the following diagnoses:&#xD;
&#xD;
        Liposarcoma (round cell or pleomorphic).&#xD;
&#xD;
        Fibrosarcoma.&#xD;
&#xD;
        Malignant fibrous histiocytoma.&#xD;
&#xD;
        Inflammatory malignant fibrous histiocytoma.&#xD;
&#xD;
        Myxoid malignant fibrous histiocytoma.&#xD;
&#xD;
        Malignant giant cell tumor.&#xD;
&#xD;
        Angiomatoid malignant fibrous histiocytoma.&#xD;
&#xD;
        Leiomyosarcoma.&#xD;
&#xD;
        Malignant hemangiopericytoma.&#xD;
&#xD;
        Rhabdomyosarcoma (embryonal, alveolar, pleomorphic or combined).&#xD;
&#xD;
        Soft tissue sarcoma resembling Ewing's sarcoma.&#xD;
&#xD;
        Synovial cell sarcoma.&#xD;
&#xD;
        Epithelioid sarcoma.&#xD;
&#xD;
        Clear cell sarcoma.&#xD;
&#xD;
        Neurofibrosarcoma.&#xD;
&#xD;
        Epithelioid schwannoma.&#xD;
&#xD;
        Malignant triton tumor.&#xD;
&#xD;
        Angiosarcoma.&#xD;
&#xD;
        Mixed malignant mesenchymoma.&#xD;
&#xD;
        Alvelar soft part sarcoma.&#xD;
&#xD;
        Malignant granular cell tumor.&#xD;
&#xD;
        All lesions must be Grade II or III. No patients with Grade I lesions will be acceptable.&#xD;
&#xD;
        Patients must have undergone a limb-sparing procedure in which all gross tumor has been&#xD;
        removed.&#xD;
&#xD;
        Clinical evaluation must reveal no evidence of metastatic disease either in regional lymph&#xD;
        nodes or more distant sites.&#xD;
&#xD;
        The soft tissue sarcoma must be on the extremity either at or distal to the shoulder joint&#xD;
        or at or distal to the hip joint.&#xD;
&#xD;
        The definitive surgical procedure for a primary lesion or for a recurrence must have been&#xD;
        performed no longer than four months from the date of randomization.&#xD;
&#xD;
        Patients must not have received any prior chemotherapy or radiotherapy for their sarcoma.&#xD;
&#xD;
        Patients without a history of any other malignant disease except basal cell carcinoma.&#xD;
&#xD;
        Patients who have not had a serious infection, active bleeding disorders, or concomitant&#xD;
        severe disease such as cirrhosis, ischemic heart disease, or evidence of severe impairment&#xD;
        of renal function.&#xD;
&#xD;
        Patients must be above the age of 30 and do not have a diagnosis of embryonal&#xD;
        rhabdomyosarcoma.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>National Cancer Institute (NCI)</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Suit HD, Russell WO, Martin RG. Sarcoma of soft tissue: clinical and histopathologic parameters and response to treatment. Cancer. 1975 May;35(5):1478-83. doi: 10.1002/1097-0142(197505)35:53.0.co;2-1.</citation>
    <PMID>1122498</PMID>
  </reference>
  <reference>
    <citation>Lindberg RD, Martin RG, Romsdahl MM, Barkley HT Jr. Conservative surgery and postoperative radiotherapy in 300 adults with soft-tissue sarcomas. Cancer. 1981 May 15;47(10):2391-7. doi: 10.1002/1097-0142(19810515)47:103.0.co;2-b.</citation>
    <PMID>7272893</PMID>
  </reference>
  <reference>
    <citation>McNeer GP, Cantin J, Chu F, Nickson JJ. Effectiveness of radiation therapy in the management of sarcoma of the soft somatic tissues. Cancer. 1968 Aug;22(2):391-7. doi: 10.1002/1097-0142(196808)22:23.0.co;2-q. No abstract available.</citation>
    <PMID>4298242</PMID>
  </reference>
  <verification_date>November 1999</verification_date>
  <study_first_submitted>November 3, 1999</study_first_submitted>
  <study_first_submitted_qc>December 9, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2002</study_first_posted>
  <last_update_submitted>March 3, 2008</last_update_submitted>
  <last_update_submitted_qc>March 3, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 4, 2008</last_update_posted>
  <keyword>Chemotherapy</keyword>
  <keyword>Radiation Therapy</keyword>
  <keyword>Sarcoma</keyword>
  <keyword>Surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

